Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00560391 · ClinicalTrials.gov registry record · Phase 1
Dasatinib in Combination With Revlimid (and Dexamethasone)
A Phase 1 study of Multiple Myeloma, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 4
- Study locations
NCT00560391: Completed Phase 1 study of Multiple Myeloma, sponsored by Bristol-Myers Squibb.
NCT00560391 is a Phase 1 study of Multiple Myeloma that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 35 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (94% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00560391, a Phase 1 study of Multiple Myeloma, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study was to determine the safety and tolerability of dasatinib when given in combination with lenalidomide and a low dose dexamethasone for the treatment of relapsed or refractory multiple myeloma.
Primary Outcome
The RP2D was based on the MTD which was defined as the maximum combined dose producing dose limiting toxicity (DLT) in \< 33% of participants treated at the individual dose levels in the combination. The MTD is considered the last dose level combination tested just below the maximum administered dose (MAD) level combination and for which DLTs were observed in less than or equal to 33% of participants during the escalation and expansion phase. If MTD was not reached Please refer to Outcome Measur
Conditions Studied
Interventions
- DRUG Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg
- DRUG Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg
- DRUG Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg
- DRUG Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg
- DRUG Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg
Study Locations (4)
Other
- Local Institution - Toulouse
- Local Institution - Vandœuvre-lès-Nancy
Arizona
- Mayo Clinic Arizona - Scottsdale
Victoria
- Local Institution - Prahran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2008-05 |
| Est. Completion | 2012-11 |
| Phase | Phase 1 |
What the finished NCT00560391 record still lists
NCT00560391 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg is the first listed.
NCT00560391 reports a single indexed study location in Other, Arizona, Victoria.
Frequently Asked Questions
What is clinical trial NCT00560391 about?
NCT00560391 is a clinical study titled "Dasatinib in Combination With Revlimid (and Dexamethasone)". The purpose of this study was to determine the safety and tolerability of dasatinib when given in combination with lenalidomide and a low dose dexamethasone for the treatment of relapsed or refractory multiple myeloma.
What is the current status of trial NCT00560391?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2008-05. Estimated completion is 2012-11.
What conditions does trial NCT00560391 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT00560391?
The interventions under investigation include: Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg (DRUG), Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg (DRUG), Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg (DRUG), Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg (DRUG), Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg (DRUG).
Who is sponsoring clinical trial NCT00560391?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00560391 being conducted?
This trial has 4 study locations across Arizona, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00560391's enrollment target sits among peer trials
35 315th of 438 higher than 120 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia